Molecular Hydrogen Therapy Enhances Immune Markers in Treg, Plasma, Tr1 Cells, and KLRG1 Expression on Tc Cells: A Case of Acute SDH With Midline Shift and Uncal Herniation Post-decompressive Craniectomy

The publication “Molecular Hydrogen Therapy Enhances Immune Markers in Treg, Plasma, Tr1 Cells, and KLRG1 Expression on Tc Cells: A Case of Acute SDH With Midline Shift and Uncal Herniation Post-decompressive Craniectomy” is organized in H2HUBB under the research focus molecular hydrogen inflammation immune study 2025 hui-fu. The publication is cited as HSU HUI-FU, HU RUEI-YANG, LU JENG-WEI, HUENG DUENG-YUAN, HO YI-JUNG, LUI SHAN-WEN, HSIEH TING-YU, WANG KUANG-YIH, LIU HSIAO-CHEN, LIU FENG-CHENG, In Vivo, 2025. This uncontrolled human study examined Molecular Hydrogen Therapy Enhances Immune Markers in Treg, Plasma, Tr1 Cells, and KLRG1 Expression on Tc Cells: A Case of Acute SDH With Midline Shift and Uncal Herniation Post-decompressive Craniectomy. The abstract describes Human participants. The abstract reports: This case suggests that molecular hydrogen therapy may be a helpful adjunct treatment for SDH with midline shift. Conventional therapies, including craniectomy, hyperbaric oxygen,…. This is an automated editorial draft based on the abstract and requires source review before publication.

Molecular hydrogen inflammation immune study 2025 hui-fu overview

Subdural hematomas (SDH), often caused by head trauma, are serious with high mortality and long-term complications. Studies show that molecular hydrogen has neuroprotective effects,… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.

Study design and hydrogen intervention

Publication type: Uncontrolled human study. Evidence type: Human clinical evidence. Research model or population: Human participants. Blinding: Unknown. Control status: Unknown.

Delivery method: Other or not reported.

Reported findings and scientific interpretation

For this molecular hydrogen inflammation immune study 2025 hui-fu, the study record reports the following: The abstract reports: This case suggests that molecular hydrogen therapy may be a helpful adjunct treatment for SDH with midline shift. Conventional therapies, including craniectomy, hyperbaric oxygen,…

These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.

How this research record was prepared

H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.

Limitations, safety, and original source

Limitations: While these findings are encouraging, further research is necessary to confirm hydrogen therapy's benefits and its role alongside traditional neurocritical care treatments.

Safety: The abstract did not provide detailed safety or adverse-event information.

This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.